Idorsia Ltd - Special Call Transcript
Good morning, good afternoon, ladies and gentlemen, and welcome to the Idorsia call on Phase III clinical data. (Operator Instructions)
Now I'd like to hand the conference over to Andrew Weiss, Head, Investor Relations and Corporate Communications. Please go ahead.
Thank you, operator. Good afternoon, and good morning to you all. This is Andrew Weiss, and I welcome everybody to our call devoted to the exciting initial data from the first pivotal study and in our Phase III program with daridorexant in patients suffering of insomnia.
Today, we are here to talk you through what we've seen and share our excitement of our first impressions on daridorexant. However, I do need to remind everybody that this is a specific call on daridorexant Phase III study, hence, please keep your questions at the end of the call in this context.
With me on the call are our CEO, Jean-Paul Clozel; our Chief Scientific Officer, Martine Clozel; and our Head -- our Global
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |